This article is more than 5 years old. Information may no longer be current.
Omni surgical system shows IOP, medication reductions in pilot study
Click Here to Manage Email Alerts
PARIS — Results from the first study of the Omni surgical system in glaucoma patients suggest a favorable safety profile and long-term reductions in IOP and IOP-lowering medications, Sight Sciences presented at the European Society of Cataract and Refractive Surgeons meeting.
The pilot study, which included 24 eyes of 19 mild to moderate primary open-angle glaucoma patients who were treated with the Omni system, found a mean IOP reduction of 40% at 18 months and a mean medication reduction of 41%.
“With its unique capability to perform two sequential outflow procedures (canal viscodilation and trabeculotomy), Omni is the only device that can target all three sources of resistance in the conventional outflow pathway. The clinical findings of this first Omni study suggest a durability and consistency of IOP lowering and medication reduction when all three sources of outflow resistance are targeted sequentially,” Ingrid Kane, MD, vice president of global medical affairs at Sight Sciences, said in the release.